

Jared M Baeten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1553455/publications.pdf>

Version: 2024-02-01

353
papers

17,550
citations

20759

60
h-index

20307

116
g-index

360
all docs

360
docs citations

360
times ranked

10371
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. <i>New England Journal of Medicine</i> , 2012, 367, 399-410.	13.9	2,665
2	Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. <i>Lancet</i> , The, 2010, 375, 2092-2098.	6.3	844
3	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	13.9	624
4	Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 19-26.	4.6	375
5	Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1 Serodiscordant Couples. <i>Journal of Infectious Diseases</i> , 2012, 205, 358-365.	1.9	291
6	HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 340-348.	0.9	270
7	Defining success with HIV pre-exposure prophylaxis. <i>Aids</i> , 2015, 29, 1277-1285.	1.0	247
8	HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. <i>Lancet</i> , The, 2019, 394, 303-313.	6.3	230
9	Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, 380-385.	0.7	229
10	HIV Subtype D Infection Is Associated with Faster Disease Progression than Subtype A in Spite of Similar Plasma HIV Loads. <i>Journal of Infectious Diseases</i> , 2007, 195, 1177-1180.	1.9	227
11	Combination HIV Prevention: Significance, Challenges, and Opportunities. <i>Current HIV/AIDS Reports</i> , 2011, 8, 62-72.	1.1	226
12	What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 463-468.	0.9	221
13	Increased risk of HIV-1 transmission in pregnancy. <i>Aids</i> , 2011, 25, 1887-1895.	1.0	219
14	Intravaginal Practices, Bacterial Vaginosis, and HIV Infection in Women: Individual Participant Data Meta-analysis. <i>PLoS Medicine</i> , 2011, 8, e1000416.	3.9	215
15	Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners. <i>Journal of Infectious Diseases</i> , 2018, 218, 16-25.	1.9	198
16	Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. <i>PLoS Medicine</i> , 2013, 10, e1001511.	3.9	192
17	Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 554-564.	4.6	175
18	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. <i>PLoS Medicine</i> , 2015, 12, e1001778.	3.9	170

#	ARTICLE	IF	CITATIONS
19	Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1 Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. <i>PLoS Medicine</i> , 2016, 13, e1002099.	3.9	166
20	HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. <i>Journal of the International AIDS Society</i> , 2019, 22, e25298.	1.2	150
21	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 824-833.	6.3	142
22	Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. <i>Aids</i> , 2007, 21, 1771-1777.	1.0	140
23	Preexposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S122-S129.	0.9	139
24	Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. <i>PLoS Medicine</i> , 2011, 8, e1001123.	3.9	130
25	Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk. <i>PLoS ONE</i> , 2010, 5, e12598.	1.1	129
26	High HIV Testing Uptake and Linkage to Care in a Novel Program of Home-Based HIV Counseling and Testing With Facilitated Referral in KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, e1-e8.	0.9	128
27	Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. <i>Aids</i> , 2013, 27, 2155-2160.	1.0	124
28	An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 333-343.	0.9	123
29	An Empiric Risk Scoring Tool for Identifying High-Risk Heterosexual HIV-1 Serodiscordant Couples for Targeted HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 339-347.	0.9	117
30	Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 362.	3.8	110
31	Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. <i>Journal of the International AIDS Society</i> , 2015, 18, 20227.	1.2	109
32	Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. <i>Lancet HIV</i> , 2020, 7, e38-e48.	2.1	106
33	Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya. <i>PLoS Medicine</i> , 2019, 16, e1002885.	3.9	105
34	Acceptability and use of a dapivirine vaginal ring in a phase III trial. <i>Aids</i> , 2017, 31, 1159-1167.	1.0	97
35	Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 1021-1028.	4.6	95
36	Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 1055-1064.	4.6	94

#	ARTICLE	IF	CITATIONS
37	Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 18-26.	1.5	94
38	Measuring the Infectiousness of Persons with HIV-1: Opportunities for Preventing Sexual HIV-1 Transmission. <i>Current HIV Research</i> , 2003, 1, 69-89.	0.2	93
39	Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 313-322.	0.9	89
40	PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003670.	3.9	87
41	Use of serum retinol-binding protein for prediction of vitamin A deficiency: effects of HIV-1 infection, protein malnutrition, and the acute phase response. <i>American Journal of Clinical Nutrition</i> , 2004, 79, 218-225.	2.2	86
42	Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. <i>Aids</i> , 2010, 24, 1975-1982.	1.0	86
43	Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine/Tenofovir Disoproxil Fumarate Preexposure Prophylaxis. <i>JAMA Internal Medicine</i> , 2015, 175, 246.	2.6	83
44	HIV-1 Prevention for HIV-1 Serodiscordant Couples. <i>Current HIV/AIDS Reports</i> , 2012, 9, 160-170.	1.1	80
45	Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1211-8.	1.9	80
46	Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. <i>The Lancet Global Health</i> , 2020, 8, e1305-e1315.	2.9	78
47	Initiation of antiretroviral therapy and viral suppression after home HIV testing and counselling in KwaZulu-Natal, South Africa, and Mbarara district, Uganda: a prospective, observational intervention study. <i>Lancet HIV</i> , 2014, 1, e68-e76.	2.1	76
48	Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. <i>PLoS ONE</i> , 2011, 6, e25828.	1.1	75
49	The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. <i>Aids</i> , 2017, 31, 2007-2016.	1.0	75
50	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. <i>Gates Open Research</i> , 2017, 1, 3.	2.0	75
51	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Annals of Internal Medicine</i> , 2021, 174, 344-352.	2.0	73
52	Injectable Contraceptive Use and Genital Ulcer Disease during the Early Phase of HIV-1 Infection Increase Plasma Virus Load in Women. <i>Journal of Infectious Diseases</i> , 2004, 189, 303-311.	1.9	72
53	PrEP rollout in Africa: status and opportunity. <i>Nature Medicine</i> , 2020, 26, 655-664.	15.2	71
54	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. <i>Gates Open Research</i> , 2017, 1, 3.	2.0	71

#	ARTICLE	IF	CITATIONS
55	Female-to-Male Infectivity of HIV-1 among Circumcised and Uncircumcised Kenyan Men. <i>Journal of Infectious Diseases</i> , 2005, 191, 546-553.	1.9	70
56	Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. <i>PLoS Medicine</i> , 2016, 13, e1002132.	3.9	70
57	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95.	2.1	70
58	Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women. , 2022, 1, .		69
59	HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 579-584.	0.9	68
60	Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. <i>Journal of the International AIDS Society</i> , 2017, 20, 21842.	1.2	67
61	Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. <i>Journal of the International AIDS Society</i> , 2020, 23, e25426.	1.2	67
62	Adolescent girls and young women's PrEP-user journey during an implementation science study in South Africa and Kenya. <i>PLoS ONE</i> , 2021, 16, e0258542.	1.1	67
63	Feasibility and acceptability of HIV self-testing among pre-exposure prophylaxis users in Kenya. <i>Journal of the International AIDS Society</i> , 2017, 20, 21234.	1.2	66
64	Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1-Infected Women: A Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2004, 189, 1466-1471.	1.9	62
65	Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda. <i>Lancet HIV</i> , 2016, 3, e212-e220.	2.1	62
66	The Influence of Hormonal Contraceptive Use on HIV-1 Transmission and Disease Progression. <i>Clinical Infectious Diseases</i> , 2007, 45, 360-369.	2.9	61
67	Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know?. <i>Current HIV/AIDS Reports</i> , 2013, 10, 142-151.	1.1	60
68	Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study. <i>Sexual Health</i> , 2018, 15, 578.	0.4	60
69	A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. <i>Aids</i> , 2011, 25, 2009-2018.	1.0	59
70	Systemic and Topical Drugs for the Prevention of HIV Infection: Antiretroviral Pre-exposure Prophylaxis. <i>Annual Review of Medicine</i> , 2013, 64, 219-232.	5.0	59
71	Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. <i>Aids</i> , 2015, 29, 1077-1085.	1.0	59
72	Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. <i>Journal of the International AIDS Society</i> , 2015, 18, 20013.	1.2	59

#	ARTICLE	IF	CITATIONS
73	Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 374-380.	0.9	57
74	Brief Report: Integration of PrEP Services Into Routine Antenatal and Postnatal Care: Experiences From an Implementation Program in Western Kenya. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 590-595.	0.9	57
75	An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 522-529.	0.9	56
76	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. <i>EClinicalMedicine</i> , 2021, 33, 100773.	3.2	55
77	Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. <i>Aids</i> , 2002, 16, 2073-2078.	1.0	54
78	Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. <i>Aids</i> , 2016, 30, 1121-1129.	1.0	54
79	Willingness of Kenyan HIV-1 Serodiscordant Couples to Use Antiretroviral-Based HIV-1 Prevention Strategies. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 116-119.	0.9	53
80	<i>My intention was a child but I was very afraid</i>: fertility intentions and HIV risk perceptions among HIV-serodiscordant couples experiencing pregnancy in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1283-1287.	0.6	53
81	Daily Oral Tenofovir and Emtricitabineâ€“Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1â€“Uninfected Men and Women. <i>Annals of Internal Medicine</i> , 2014, 161, 11.	2.0	51
82	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 72-77.	0.9	50
83	Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIVâ€“1 acquisition: a secondary analysis from a randomized, placeboâ€“controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25634.	1.2	49
84	â€“If I am given antiretrovirals I will think I am nearing the graveâ€“TM. <i>Aids</i> , 2014, 28, 227-233.	1.0	47
85	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1â€“Serodiscordant Couples. <i>Journal of Infectious Diseases</i> , 2015, 211, 1451-1460.	1.9	47
86	â€œSince both of us are using antiretrovirals, we have been supportive to each otherâ€“: facilitators and barriers of preâ€“exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya. <i>Journal of the International AIDS Society</i> , 2016, 19, 21134.	1.2	47
87	Intimate Partner Violence and Self-Reported Pre-exposure Prophylaxis Interruptions Among HIV-Negative Partners in HIV Serodiscordant Couples in Kenya and Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 154-159.	0.9	47
88	Global implementation of PrEP for HIV prevention: setting expectations for impact. <i>Journal of the International AIDS Society</i> , 2019, 22, e25370.	1.2	45
89	<i>I Knew I Would Be Safer</i>. Experiences of Kenyan HIV Serodiscordant Couples Soon After Pre-Exposure Prophylaxis (PrEP) Initiation. <i>AIDS Patient Care and STDs</i> , 2016, 30, 78-83.	1.1	44
90	Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. <i>Lancet HIV</i> , 2017, 4, e449-e456.	2.1	44

#	ARTICLE	IF	CITATIONS
91	Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. <i>Lancet HIV</i> ,the, 2020, 7, e582-e592.	2.1	44
92	Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. <i>Aids</i> , 2015, 29, 2353-2359.	1.0	43
93	Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. <i>Lancet HIV</i> ,the, 2015, 2, e279-e287.	2.1	43
94	“I Did Not Want to Give Birth to a Child Who has HIV”: Experiences Using PrEP During Pregnancy Among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 259-265.	0.9	43
95	Simultaneous quantitation of multiple contraceptive hormones in human serum by LC-MS/MS. <i>Contraception</i> , 2018, 97, 363-369.	0.8	43
96	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.	3.2	42
97	Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal and child health and family planning clinics. <i>Aids</i> , 2019, 33, 1369-1378.	1.0	42
98	Vitamin A Supplementation and Human Immunodeficiency Virus Type 1 Shedding in Women: Results of a Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2002, 185, 1187-1191.	1.9	41
99	Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25636.	1.2	41
100	Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. <i>Lancet HIV</i> ,the, 2021, 8, e130-e137.	2.1	41
101	Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. <i>Journal of Infectious Diseases</i> , 2016, 214, 1050-1057.	1.9	40
102	High-dose Valacyclovir HSV-2 Suppression Results in Greater Reduction in Plasma HIV-1 Levels Compared With Standard Dose Acyclovir Among HIV-1/HSV-2 Coinfected Persons: A Randomized, Crossover Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1912-1917.	1.9	38
103	Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. <i>Aids</i> , 2014, 28, 2771-2776.	1.0	38
104	Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial. <i>AIDS and Behavior</i> , 2020, 24, 1432-1442.	1.4	38
105	Household-Based HIV Counseling and Testing as a Platform for Referral to HIV Care and Medical Male Circumcision in Uganda: A Pilot Evaluation. <i>PLoS ONE</i> , 2012, 7, e51620.	1.1	38
106	Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. <i>Aids</i> , 2014, 28, 1825-1830.	1.0	37
107	Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, S15-S22.	0.9	37
108	HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Pre-Exposure Prophylaxis During Pregnancy. <i>AIDS Patient Care and STDs</i> , 2018, 32, 538-544.	1.1	37

#	ARTICLE	IF	CITATIONS
109	I just believe there is a risk of understanding of undetectable equals untransmissible (U=U) among health providers and HIV-negative partners in serodiscordant relationships in Kenya. <i>Journal of the International AIDS Society</i> , 2020, 23, e25466.	1.2	37
110	Daily Short Message Service Surveys to Measure Sexual Behavior and Pre-exposure Prophylaxis Use Among Kenyan Men and Women. <i>AIDS and Behavior</i> , 2013, 17, 2977-2985.	1.4	36
111	A Prospective Study of Contraceptive Use Among African Women in HIV-1 Serodiscordant Partnerships. <i>Sexually Transmitted Diseases</i> , 2010, 37, 621-628.	0.8	36
112	Understanding the Potential Impact of a Combination HIV Prevention Intervention in a Hyper-Endemic Community. <i>PLoS ONE</i> , 2013, 8, e54575.	1.1	36
113	Vitamin A Deficiency and the Acute Phase Response Among HIV-1-Infected and Uninfected Women in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 243-249.	0.9	34
114	Antiretroviral-Based HIV-1 Prevention: Antiretroviral Treatment and Pre-Exposure Prophylaxis. <i>Antiviral Therapy</i> , 2012, 17, 1483-1493.	0.6	34
115	Beyond HIV prevention: everyday life priorities and demand for PrEP among Ugandan HIV serodiscordant couples. <i>Journal of the International AIDS Society</i> , 2019, 22, e25225.	1.2	34
116	Outside Sexual Partnerships and Risk of HIV Acquisition for HIV Uninfected Partners in African HIV Serodiscordant Partnerships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 65-71.	0.9	33
117	Hormonal contraceptive use and risk of HIV-1 disease progression. <i>Aids</i> , 2013, 27, 261-267.	1.0	33
118	HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact. <i>Journal of Infectious Diseases</i> , 2013, 208, 189-191.	1.9	33
119	High Medication Adherence During Periconception Periods Among HIV-1-Uninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 91-97.	0.9	33
120	Delay of Antiretroviral Therapy Initiation Is Common in East African HIV-Infected Individuals in Serodiscordant Partnerships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 436-442.	0.9	33
121	PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial. <i>BMJ Open</i> , 2019, 9, e025122.	0.8	33
122	A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa. <i>BMC Health Services Research</i> , 2021, 21, 888.	0.9	33
123	Unreported Antiretroviral Use by HIV-1-Infected Participants Enrolling in a Prospective Research Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e90-e94.	0.9	32
124	Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples. <i>The Lancet Global Health</i> , 2014, 2, e664-e671.	2.9	32
125	Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 148-154.	0.5	32
126	Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 580-589.	0.9	32

#	ARTICLE	IF	CITATIONS
127	Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. <i>Aids</i> , 2018, 32, 1707-1713.	1.0	32
128	Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 265-273.	1.0	31
129	Delivering safer conception services to HIV serodiscordant couples in Kenya: perspectives from healthcare providers and HIV serodiscordant couples. <i>Journal of the International AIDS Society</i> , 2017, 20, 21309.	1.2	31
130	Fertility Intentions, Pregnancy, and Use of PrEP and ART for Safer Conception Among East African HIV Serodiscordant Couples. <i>AIDS and Behavior</i> , 2018, 22, 1758-1765.	1.4	31
131	Design of a care pathway for pharmacy-based PrEP delivery in Kenya: results from a collaborative stakeholder consultation. <i>BMC Health Services Research</i> , 2020, 20, 1034.	0.9	31
132	Topical Microbicides in HIV Prevention: State of the Promise. <i>Annual Review of Medicine</i> , 2020, 71, 361-377.	5.0	30
133	PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options. <i>Cell Host and Microbe</i> , 2020, 27, 502-506.	5.1	30
134	Successful increase in contraceptive uptake among Kenyan HIV-1-serodiscordant couples enrolled in an HIV-1 prevention trial. <i>Aids</i> , 2009, 23, S89-S95.	1.0	29
135	Fertility Decision-Making Among Kenyan HIV-Serodiscordant Couples Who Recently Conceived: Implications for Safer Conception Planning. <i>AIDS Patient Care and STDs</i> , 2015, 29, 510-516.	1.1	29
136	Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, e115-e118.	0.9	29
137	PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	29
138	Implementation of a comprehensive safer conception intervention for HIV serodiscordant couples in Kenya: uptake, use and effectiveness. <i>Journal of the International AIDS Society</i> , 2019, 22, e25261.	1.2	28
139	The arc of HIV epidemics in sub-Saharan Africa. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 354-365.	1.5	28
140	Facilitators and Barriers of Antiretroviral Therapy Initiation among HIV Discordant Couples in Kenya: Qualitative Insights from a Pre-Exposure Prophylaxis Implementation Study. <i>PLoS ONE</i> , 2016, 11, e0168057.	1.1	28
141	A Prospective Study of the Effect of Pregnancy on CD4 Counts and Plasma HIV-1 RNA Concentrations of Antiretroviral-Naive HIV-1-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 231-236.	0.9	27
142	“I Just Decided to Stop”: Understanding PrEP Discontinuation Among Individuals Initiating PrEP in HIV Care Centers in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, e150-e158.	0.9	27
143	Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 206-212.	0.9	26
144	The role of costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya. <i>Journal of the International AIDS Society</i> , 2019, 22, e25296.	1.2	26

#	ARTICLE	IF	CITATIONS
145	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq1 1 0z784314 rgBT /Over	1.1	25
146	Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. PLoS ONE, 2015, 10, e0128857.	1.1	25
147	Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study. Journal of Infectious Diseases, 2017, 216, 1561-1568.	1.9	25
148	ScaleÂup of PrEP integrated in public health HIV care clinics: a protocol for a stepped-wedge cluster-randomized rollout in Kenya. Implementation Science, 2018, 13, 118.	2.5	25
149	Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. Aids, 2016, 30, 31-35.	1.0	24
150	Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 566-572.	0.9	24
151	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Clinical Infectious Diseases, 2020, 70, 2143-2151.	2.9	24
152	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq0 0 0z784314 rgBT /Over	1.1	24
153	Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda. PLoS ONE, 2020, 15, e0241399.	1.1	24
154	Male circumcision and HIV risks and benefits for women. Lancet, The, 2009, 374, 182-184.	6.3	23
155	Oral antiretroviral chemoprophylaxis. Current Opinion in HIV and AIDS, 2012, 7, 514-519.	1.5	23
156	Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. BMC Infectious Diseases, 2016, 16, 571.	1.3	23
157	Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 206-211.	0.9	23
158	Perinatal outcomes following maternal preâ€exposure prophylaxis (Pr<scp>EP</scp>) use during pregnancy: results from a large Pr<scp>EP</scp> implementation program in Kenya. Journal of the International AIDS Society, 2019, 22, e25378.	1.2	23
159	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE) Tj ETQq1 1 0,784314 rgBT /Over	0.7	23
160	Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial. Lancet HIV,the, 2022, 9, e464-e473.	2.1	23
161	Quantifying Ongoing HIV-1 Exposure in HIV-1â€Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1. Journal of Infectious Diseases, 2012, 206, 1299-1308.	1.9	22
162	Host Genetic and Viral Determinants of HIV-1 RNA Set Point among HIV-1 Seroconverters from Sub-Saharan Africa. Journal of Virology, 2015, 89, 2104-2111.	1.5	22

#	ARTICLE	IF	CITATIONS
163	Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 513-520.	2.9	22
164	Acceptability and Feasibility of Pharmacy-Based Delivery of Pre-Exposure Prophylaxis in Kenya: A Qualitative Study of Client and Provider Perspectives. <i>AIDS and Behavior</i> , 2021, 25, 3871-3882.	1.4	22
165	Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. <i>AIDS and Behavior</i> , 2015, 19, 811-820.	1.4	21
166	Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. <i>American Journal of Epidemiology</i> , 2015, 182, 848-856.	1.6	21
167	Gendered differences in the perceived risks and benefits of oral PrEP among HIV-serodiscordant couples in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1000-1006.	0.6	21
168	Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships. <i>AIDS and Behavior</i> , 2018, 22, 3718-3725.	1.4	21
169	Integrated Strategies for Combination HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S213-S220.	0.9	20
170	Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis. <i>Lancet HIV</i> , 2016, 3, e275-e282.	2.1	20
171	Dapivirine Vaginal Ring for HIV-1 Prevention. <i>New England Journal of Medicine</i> , 2017, 376, 994-996.	13.9	20
172	A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. <i>BMC Infectious Diseases</i> , 2017, 17, 496.	1.3	20
173	Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 330-338.	0.9	20
174	HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya. <i>Trials</i> , 2019, 20, 396.	0.7	20
175	PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 265-274.	0.9	20
176	Uptake and impact of facility-based HIV self-testing on PrEP delivery: a pilot study among young women in Kisumu, Kenya. <i>Journal of the International AIDS Society</i> , 2020, 23, e25561.	1.2	20
177	Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial. <i>AIDS and Behavior</i> , 2021, 25, 1112-1119.	1.4	20
178	Association between medical male circumcision and HIV risk compensation among heterosexual men: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2021, 9, e932-e941.	2.9	20
179	Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 214, 212-215.	1.9	19
180	Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV serodiscordant couples in East Africa: a qualitative evaluation study in Uganda. <i>Journal of the International AIDS Society</i> , 2018, 21, e25113.	1.2	19

#	ARTICLE	IF	CITATIONS
181	HIV self-testing and oral pre-exposure prophylaxis are empowering for sex workers and their intimate partners: a qualitative study in Uganda. <i>Journal of the International AIDS Society</i> , 2021, 24, e25782.	1.2	19
182	Relationship between markers of HIV-1 disease progression and serum Î²-carotene concentrations in Kenyan women. <i>International Journal of STD and AIDS</i> , 2007, 18, 202-206.	0.5	18
183	Fertility Intentions and Interest in Early Antiretroviral Therapy Among East African HIV-1-Infected Individuals in Serodiscordant Partnerships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e33-e35.	0.9	18
184	Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. <i>Aids</i> , 2014, 28, 1977-1982.	1.0	18
185	Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 119-128.	0.9	18
186	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 1534-1540.	1.9	18
187	The Incremental Cost of Delivering PrEP as a Bridge to ART for HIV Serodiscordant Couples in Public HIV Care Clinics in Kenya. <i>AIDS Research and Treatment</i> , 2019, 2019, 1-8.	0.3	18
188	Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25491.	1.2	18
189	Pharmacy delivery to expand the reach of PrEP in Africa. <i>Journal of the International AIDS Society</i> , 2020, 23, e25619.	1.2	18
190	Lottery incentives have short-term impact on ART initiation among men: results from a randomized pilot study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25519.	1.2	18
191	Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2016, 213, 551-555.	1.9	17
192	What motivates serodiscordant couples to prevent HIV transmission within their relationships: findings from a PrEP implementation study in Kenya. <i>Culture, Health and Sexuality</i> , 2018, 20, 625-639.	1.0	17
193	Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. <i>Sexually Transmitted Infections</i> , 2021, 97, 249-255.	0.8	17
194	Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. <i>AIDS and Behavior</i> , 2021, 25, 2430-2440.	1.4	17
195	Estimating the Cost-Effectiveness of Pre-Exposure Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South Africa. <i>PLoS ONE</i> , 2015, 10, e0115511.	1.1	17
196	Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial. <i>The Lancet Global Health</i> , 2021, 9, e1730-e1739.	2.9	17
197	Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 488-492.	0.9	16
198	Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 330-337.	0.9	16

#	ARTICLE	IF	CITATIONS
199	Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status. <i>Vaccine</i> , 2018, 36, 7025-7032.	1.7	16
200	Cost of Integrating Noncommunicable Disease Screening Into Home-Based HIV Testing and Counseling in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 522-526.	0.9	16
201	Comprehensive HIV risk reduction interventions for 2020 and beyond. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 423-432.	1.5	16
202	First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 304-310.	0.9	16
203	Sexually transmitted infections among African women: an opportunity for combination sexually transmitted infection/HIV prevention. <i>Aids</i> , 2020, 34, 651-658.	1.0	16
204	Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study. <i>Lancet HIV</i> , 2021, 8, e495-e501.	2.1	16
205	Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. <i>Gates Open Research</i> , 2020, 4, 29.	2.0	16
206	Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1. <i>PLoS Pathogens</i> , 2017, 13, e1006703.	2.1	16
207	“You are not a man”: a multi-method study of trans stigma and risk of HIV and sexually transmitted infections among trans men in Uganda. <i>Journal of the International AIDS Society</i> , 2021, 24, e25860.	1.2	16
208	A one-stop shop model for improved efficiency of pre-exposure prophylaxis delivery in public clinics in western Kenya: a mixed methods implementation science study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25845.	1.2	16
209	Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). <i>PLoS ONE</i> , 2022, 17, e0267780.	1.1	16
210	Preferences for Daily or Intermittent Pre-exposure Prophylaxis Regimens and Ability to Anticipate Sex Among HIV Uninfected Members of Kenyan HIV Serodiscordant Couples. <i>AIDS and Behavior</i> , 2014, 18, 1701-1711.	1.4	15
211	Frequency of False Positive Rapid HIV Serologic Tests in African Men and Women Receiving PrEP for HIV Prevention: Implications for Programmatic Roll-Out of Biomedical Interventions. <i>PLoS ONE</i> , 2015, 10, e0123005.	1.1	15
212	Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. <i>Journal of Infectious Diseases</i> , 2015, 211, 1943-1952.	1.9	15
213	Concordance of self-reported hormonal contraceptive use and presence of exogenous hormones in serum among African women. <i>Contraception</i> , 2018, 97, 357-362.	0.8	15
214	Benefits of male circumcision for MSM: evidence for action. <i>The Lancet Global Health</i> , 2019, 7, e388-e389.	2.9	15
215	Dynamic Perceived HIV Risk and Sexual Behaviors Among Young Women Enrolled in a PrEP Trial in Kenya: A Qualitative Study. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	15
216	Tenofovir alafenamide for HIV infection: is less more?. <i>Lancet, The</i> , 2015, 385, 2559-2560.	6.3	14

#	ARTICLE	IF	CITATIONS
217	Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5379-5386.	1.4	14
218	Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. <i>AIDS and Behavior</i> , 2017, 21, 2173-2179.	1.4	14
219	Client-Centered Adherence Counseling with Adherence Measurement Feedback to Support Use of the Dapivirine Ring in MTN-025 (The HOPE Study). <i>AIDS and Behavior</i> , 2021, 25, 447-458.	1.4	14
220	Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 867-871.	1.0	14
221	Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. <i>Gates Open Research</i> , 2020, 4, 29.	2.0	14
222	A clinic-based tablet application to support safer conception among HIV serodiscordant couples in Kenya: feasibility and acceptability study. <i>MHealth</i> , 2019, 5, 4-4.	0.9	14
223	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15029.	0.5	14
224	Development of a targeted educational intervention to increase pre-exposure prophylaxis uptake among cisgender men and transgender individuals who have sex with men and use methamphetamine in Seattle (WA, USA). <i>Sexual Health</i> , 2019, 16, 139-147.	0.4	14
225	Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and examples of successful health service models of PrEP implementation. <i>Sexual Health</i> , 2018, 15, 481.	0.4	13
226	Integrating PrEP into HIV care clinics could improve partner testing services and reinforce mutual support among couples: provider views from a PrEP implementation project in Kenya. <i>Journal of the International AIDS Society</i> , 2019, 22, e25303.	1.2	13
227	Short Message Service (SMS) Surveys Assessing Pre-exposure Prophylaxis (PrEP) Adherence and Sexual Behavior are Highly Acceptable Among HIV-Uninfected Members of Serodiscordant Couples in East Africa: A Mixed Methods Study. <i>AIDS and Behavior</i> , 2019, 23, 1267-1276.	1.4	13
228	Age-Specific Risk Scores Do Not Improve HIV-1 Prediction Among Women in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 156-164.	0.9	13
229	Is HIV Self-Testing a Strategy to Increase Repeat Testing Among Pregnant and Postpartum Women? A Pilot Mixed Methods Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 365-371.	0.9	13
230	Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program. <i>Clinical Infectious Diseases</i> , 2020, 71, e509-e512.	2.9	13
231	Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial. <i>Trials</i> , 2022, 23, .	0.7	13
232	HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission. <i>Aids</i> , 2014, 28, 235-243.	1.0	12
233	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. <i>Journal of Virology</i> , 2016, 90, 9855-9861.	1.5	12
234	A cross-sectional analysis of <i>Trichomonas vaginalis</i> infection among heterosexual HIV-1 serodiscordant African couples. <i>Sexually Transmitted Infections</i> , 2017, 93, 520-529.	0.8	12

#	ARTICLE	IF	CITATIONS
235	The role of male partners in women's participation in research during pregnancy: a case study from the partners demonstration project. <i>Reproductive Health</i> , 2017, 14, 160.	1.2	12
236	Safer conception among HIV-1 serodiscordant couples in East Africa: understanding knowledge, attitudes, and experiences. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 973-981.	0.6	12
237	Current and future contraceptive options for women living with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1-12.	0.9	12
238	Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women. <i>Journal of the International AIDS Society</i> , 2019, 22, e25257.	1.2	12
239	Training health care providers to provide PrEP for HIV serodiscordant couples attending public health facilities in Kenya. <i>Global Public Health</i> , 2019, 14, 1524-1534.	1.0	12
240	Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa. <i>BMJ Open</i> , 2019, 9, e027227.	0.8	12
241	Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE. <i>AIDS and Behavior</i> , 2019, 23, 504-512.	1.4	12
242	Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 42-48.	1.5	12
243	"Now that PrEP is reducing the risk of transmission of HIV, why then do you still insist that we use condoms?" - the condom quandary among PrEP users and health care providers in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 92-100.	0.6	12
244	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. <i>Clinical Infectious Diseases</i> , 2021, 72, 486-489.	2.9	12
245	Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25744.	1.2	12
246	Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e47-e51.	0.9	12
247	Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 251-260.	0.9	12
248	Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk?. <i>Contraception</i> , 2017, 95, 424-430.	0.8	11
249	No Evidence of Sexual Risk Compensation Following PrEP Initiation Among Heterosexual HIV Serodiscordant Couples in Kenya and Uganda. <i>AIDS and Behavior</i> , 2020, 24, 1365-1375.	1.4	11
250	Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 149-152.	0.9	11
251	Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States. <i>Journal of the International AIDS Society</i> , 2019, 22, e25433.	1.2	10
252	Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 197-201.	0.9	10

#	ARTICLE	IF	CITATIONS
253	Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. <i>Cell Reports Medicine</i> , 2020, 1, 100096.	3.3	10
254	Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. <i>International Journal of Infectious Diseases</i> , 2020, 97, 365-370.	1.5	10
255	Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2022, 75, 1873-1882.	2.9	10
256	Circumcision of Male Children for Reduction of Future Risk for HIV: Acceptability among HIV Serodiscordant Couples in Kampala, Uganda. <i>PLoS ONE</i> , 2011, 6, e22254.	1.1	9
257	Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting. <i>AIDS and Behavior</i> , 2013, 17, 3108-3119.	1.4	9
258	Amplifying the Population Health Benefits of PrEP for HIV Prevention. <i>Journal of Infectious Diseases</i> , 2018, 217, 1509-1511.	1.9	9
259	Brief Report: PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 41-45.	0.9	9
260	Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women. <i>Frontiers in Pharmacology</i> , 2019, 10, 401.	1.6	9
261	Lessons from PrEP: A Qualitative Study Investigating How Clinical and Policy Experts Weigh Ethics and Evidence When Evaluating Preventive Medications for Use in Pregnant and Breastfeeding Women. <i>AIDS and Behavior</i> , 2019, 23, 1858-1870.	1.4	9
262	Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the “PrEP as a bridge to ART” strategy. <i>BMC Public Health</i> , 2020, 20, 1621.	1.2	9
263	Pills, Injections, Rings, or Implants? PrEP Formulation Preferences of PrEP-Experienced African Women for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, e30-e32.	0.9	9
264	Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis. <i>Sexually Transmitted Diseases</i> , 2016, 43, 471-475.	0.8	8
265	“I never thought that it would happen” “I never thought that it would happen” Experiences of HIV seroconverters among HIV-discordant partnerships in a prospective HIV prevention study in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1586-1589.	0.6	8
266	Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxil Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 907-910.	1.9	8
267	Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus-Infected Persons in Serodiscordant Partnerships. <i>Sexually Transmitted Diseases</i> , 2017, 44, 58-62.	0.8	8
268	Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. <i>Epidemics</i> , 2018, 23, 34-41.	1.5	8
269	Perceptions of pregnancy occurring among HIV-serodiscordant couples in Kenya. <i>Reproductive Health</i> , 2019, 16, 85.	1.2	8
270	A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. <i>Aids</i> , 2019, 33, 1995-2004.	1.0	8

#	ARTICLE	IF	CITATIONS
271	Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring. <i>Clinical Infectious Diseases</i> , 2019, 69, 523-529.	2.9	8
272	Health Care Providers as Agents of Change: Integrating PrEP With Other Sexual and Reproductive Health Services for Adolescent Girls and Young Women. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	8
273	Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public sector. <i>BMC Health Services Research</i> , 2021, 21, 823.	0.9	8
274	Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e22.	0.5	8
275	Implementation strategies for integrating pre-exposure prophylaxis for HIV prevention and family planning services for adolescent girls and young women in Kenya: a qualitative study. <i>BMC Health Services Research</i> , 2022, 22, 422.	0.9	8
276	Effect of HIV Self-Testing on PrEP Adherence Among Gender-Diverse Sex Workers in Uganda: A Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 381-389.	0.9	8
277	Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial. <i>PLoS ONE</i> , 2022, 17, e0266665.	1.1	8
278	HIV-1 Infection Alters the Retinol-Binding Protein:Transthyretin Ratio Even in the Absence of the Acute Phase Response. <i>Journal of Nutrition</i> , 2006, 136, 1624-1629.	1.3	7
279	Pre-exposure prophylaxis to intensify the fight against HIV. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 443-445.	4.6	7
280	Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial. <i>AIDS and Behavior</i> , 2016, 20, 2639-2643.	1.4	7
281	Tenofovir alafenamide for HIV: time to switch?. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 3-5.	4.6	7
282	Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 606-615.	1.0	7
283	Electronic health record tools to catalyse PrEP conversations. <i>Lancet HIV,the</i> , 2019, 6, e644-e645.	2.1	7
284	A Field Evaluation of Point-of-Care Creatinine Testing Within a Large PrEP Implementation Program in Western Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e8-e10.	0.9	7
285	It's Time to Make the Time to Viral Suppression After HIV Diagnosis a Metric of HIV Care Success. <i>Journal of Infectious Diseases</i> , 2019, 219, 845-847.	1.9	7
286	Lessons on PrEP from the SEARCH study in east Africa. <i>Lancet HIV,the</i> , 2020, 7, e219-e220.	2.1	7
287	Process evaluation of PrEP implementation in Kenya: adaptation of practices and contextual modifications in public HIV care clinics. <i>Journal of the International AIDS Society</i> , 2021, 24, e25799.	1.2	7
288	HIV drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25833.	1.2	7

#	ARTICLE	IF	CITATIONS
289	New biomedical strategies for HIV-1 prevention in women. <i>Current Infectious Disease Reports</i> , 2008, 10, 490-498.	1.3	6
290	Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial. <i>Sexually Transmitted Diseases</i> , 2012, 39, 21-24.	0.8	6
291	Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 91-96.	0.9	6
292	Comparison of short messaging service self-reported adherence with other adherence measures in a demonstration project of HIV preexposure prophylaxis in Kenya and Uganda. <i>Aids</i> , 2018, 32, 2237-2245.	1.0	6
293	Implementation of a fidelity monitoring process to assess delivery of an evidence-based adherence counseling intervention in a multi-site biomedical HIV prevention study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1082-1091.	0.6	6
294	Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. <i>Aids</i> , 2020, 34, 197-202.	1.0	6
295	Associations between schistosomiasis and HIV acquisition risk in four prospective cohorts: a nested case-control analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25534.	1.2	6
296	Cost of pre-exposure prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya. <i>PLoS ONE</i> , 2021, 16, e0249625.	1.1	6
297	Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa. <i>Vaccine</i> , 2021, 39, 4751-4758.	1.7	6
298	HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. <i>Nature Reviews Urology</i> , 2022, 19, 7-15.	1.9	6
299	Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study. <i>BMC Public Health</i> , 2021, 21, 2041.	1.2	6
300	<i>Mycobacterium tuberculosis</i> -Specific T-Cell Responses Are Impaired During Late Pregnancy With Elevated Biomarkers of Tuberculosis Risk Postpartum. <i>Journal of Infectious Diseases</i> , 2022, 225, 1663-1674.	1.9	6
301	PrEP Gives the Woman the Control: Healthcare Worker Perspectives on Using pre-Exposure Prophylaxis (PrEP) During Pregnancy and Postpartum in Kenya. <i>Journal of the International Association of Providers of AIDS Care</i> , 2022, 21, 232595822211110.	0.6	6
302	Serodiscordancy and HIV prevention in sub-Saharan Africa. <i>Lancet, The</i> , 2013, 381, 1519-1521.	6.3	5
303	Contraception and sexually transmitted infections: risks and benefits, hypotheses and evidence. <i>The Lancet Global Health</i> , 2015, 3, e430-e431.	2.9	5
304	Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1787-1789.	1.9	5
305	Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 184-189.	0.9	5
306	Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women. <i>Aids</i> , 2019, 33, 2125-2136.	1.0	5

#	ARTICLE	IF	CITATIONS
307	Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. <i>Drugs</i> , 2020, 80, 1881-1888.	4.9	5
308	Administrative and Related Barriers to Covering the Costs of Preexposure Prophylaxis at a Safety-net Clinic in Seattle, Washington. <i>Clinical Infectious Diseases</i> , 2020, 71, 2509-2512.	2.9	5
309	Sexual Behavior and Perceived HIV Risk Among HIV-Negative Members of Serodiscordant Couples in East Africa. <i>AIDS and Behavior</i> , 2020, 24, 2082-2090.	1.4	5
310	CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions. <i>Cell Reports Medicine</i> , 2021, 2, 100322.	3.3	5
311	Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2801-2814.	1.4	5
312	Estimating PMTCT's Impact on Heterosexual HIV Transmission: A Mathematical Modeling Analysis. <i>PLoS ONE</i> , 2015, 10, e0134271.	1.1	5
313	Protocol Development for HMU! (HIV Prevention for Methamphetamine Users), a Study of Peer Navigation and Text Messaging to Promote Pre-Exposure Prophylaxis Adherence and Persistence Among People Who Use Methamphetamine: Qualitative Focus Group and Interview Study. <i>JMIR Formative Research</i> , 2020, 4, e18118.	0.7	5
314	Health Care Worker Perspectives of HIV Pre-exposure Prophylaxis Service Delivery in Central Uganda. <i>Frontiers in Public Health</i> , 2022, 10, 658826.	1.3	5
315	Integrating PrEP delivery in public health family planning clinics: a protocol for a pragmatic stepped wedge cluster randomized trial in Kenya. <i>Implementation Science Communications</i> , 2021, 2, 135.	0.8	5
316	A Scoring Tool to Identify East African HIV-1 Serodiscordant Partnerships with a High Likelihood of Pregnancy. <i>PLoS ONE</i> , 2015, 10, e0145515.	1.1	4
317	Estimating the impact of universal antiretroviral therapy for HIV serodiscordant couples through home HIV testing: insights from mathematical models. <i>Journal of the International AIDS Society</i> , 2016, 19, 20864.	1.2	4
318	Welcome to the preexposure prophylaxis revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 1-2.	1.5	4
319	High Levels of Viral Suppression Among East African HIV-Infected Women and Men in Serodiscordant Partnerships Initiating Antiretroviral Therapy with High CD4 Counts and During Pregnancy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 140-147.	0.5	4
320	Alignment of PrEP use and effective contraceptive use among East African women in HIV serodiscordant partnerships. <i>International Journal of STD and AIDS</i> , 2020, 31, 1263-1271.	0.5	4
321	Implementation of a fully remote randomized clinical trial with cardiac monitoring. <i>Communications Medicine</i> , 2021, 1, .	1.9	4
322	Targeted Implementation of HIV Self-Testing Increases Testing Uptake Among Partners of Index Persons Known to Have HIV in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 524-529.	0.9	4
323	High HIV incidence among young women in South Africa: Data from a large prospective study. <i>PLoS ONE</i> , 2022, 17, e0269317.	1.1	4
324	Mannose-binding lectin and ficolin-2 do not influence humoral immune response to hepatitis B vaccine. <i>Vaccine</i> , 2014, 32, 4772-4777.	1.7	3

#	ARTICLE	IF	CITATIONS
325	Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1052-1060.	0.9	3
326	Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 38-43.	0.9	3
327	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz338.	0.4	3
328	Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. <i>AJOB Empirical Bioethics</i> , 2019, 10, 79-87.	0.8	3
329	HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa. <i>Aids</i> , 2019, 33, 735-744.	1.0	3
330	Next-Generation Preexposure Prophylaxis: Choices For Effective HIV Prevention. <i>Journal of Infectious Diseases</i> , 2020, 221, 1387-1389.	1.9	3
331	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. <i>Aids</i> , 2020, 34, 559-567.	1.0	3
332	Perceived Social Influences on Women's Decisions to use Medications not Studied in Pregnancy. A Qualitative Ethical Analysis of Preexposure Prophylaxis Implementation Research in Kenya. <i>Journal of Empirical Research on Human Research Ethics</i> , 2021, 16, 225-237.	0.6	3
333	Rapid Antiretroviral Therapy Initiation for Women in an HIV-1 Prevention Clinical Trial Experiencing Primary HIV-1 Infection during Pregnancy or Breastfeeding. <i>PLoS ONE</i> , 2015, 10, e0140773.	1.1	3
334	Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells. <i>Journal of Virological Methods</i> , 2014, 199, 17-24.	1.0	2
335	Cost-effectiveness of HIV Prevention Interventions: Estimates from Real-world Implementation Needed. <i>EClinicalMedicine</i> , 2019, 10, 8-9.	3.2	2
336	Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007886.	1.3	2
337	ECHO: context and limitations – Authors' reply. <i>Lancet</i> , The, 2020, 395, e27.	6.3	2
338	Brief Report: Bacterial Vaginosis and Risk of HIV Infection in the Context of CD101 Gene Variation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 584-587.	0.9	2
339	The Utility of SMS to Report Male Partner HIV Self-testing Outcomes Among Women Seeking Reproductive Health Services in Kenya: Cohort Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e15281.	1.8	2
340	Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	2
341	PrEP for HIV: grade A for evidence but pending for impact. <i>Nature Reviews Urology</i> , 2019, 16, 570-571.	1.9	1
342	HIV service delivery innovation in high-prevalence settings. <i>Lancet HIV</i> , the, 2020, 7, e378-e379.	2.1	1

#	ARTICLE	IF	CITATIONS
343	Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception. <i>Contraception: X</i> , 2020, 2, 100026.	0.6	1
344	Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1147-1149.	1.0	1
345	Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa. <i>BMC Women's Health</i> , 2021, 21, 175.	0.8	1
346	Effects of the Waya Intervention on Marital Satisfaction and HIV Risk Behaviors in Western Kenya: A Pre-Post Study Design. <i>Archives of Sexual Behavior</i> , 2022, 51, 3689-3701.	1.2	1
347	Using an on-site modular training approach to amplify prep service delivery in public health facilities in Kenya. <i>PLOS Global Public Health</i> , 2022, 2, e0000092.	0.5	1
348	Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	1
349	Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring. <i>AIDS and Behavior</i> , 2022, , .	1.4	1
350	A novel "HIV salience and Perception" scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda. <i>AIDS and Behavior</i> , 2023, 27, 279-289.	1.4	1
351	Response to "Being prepared to evaluate pregnancy PrEP". <i>Journal of the International AIDS Society</i> , 2019, 22, e25440.	1.2	0
352	Sexual Behaviors After PrEP Discontinuation Among HIV Serodiscordant Couples in Kenya and Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 174-181.	0.9	0
353	Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0